30results about How to "Meet the requirements of clinical application" patented technology

The invention relates to the immunoassay medical field, in particularly provides a chemiluminescence immunoassay test kit and a preparing method thereof for pro gastrin releasing peptide (31-98). Through adopting Biotin-Streptoavidin system coated antibody, the invention can improve antibody coating efficiency, and can improve the sensitivity at the same time. The test kit provides diagnosis of small-cell lung cancer with accurate chemiluminescence test kit which has simple operation and sensitive result detecting, so as to meet the requirements in clinical diagnosis.

The invention relates to doped black phosphorus quantum dot thermal treatment syringeability bone cement as well as the preparation and the application thereof. A self-cured component is mixed with a heating nano material so as to obtain a modified bone cement solid-phase powder, wherein an alpha-tricalcium phosphate material functions as coating and carrying, and PLGA (Plgapoly Lactic-Co-Glycolic Acid) / black phosphorus quantum dots function as heating; by taking sodium phosphate as a main body and phosphorylated chitosan, hydroxypropyl methyl cellulose and gelatin as modifiers, preparing a neutral bone cement curing liquid so as to improve the syringeability of a formula; mixing the bone cement solid-phase powder with the curing liquid, so as to obtain a cured product. A main component, namely, hydroxyapatite, of the cured product, can be increased, and the PLGA and a black phosphorus material have very good degradation properties inside biological bodies. The doped black phosphorus quantum dot thermal treatment syringeability bone cement has the advantages of being simple and convenient in preparation method, simple in raw material and applicable to large-scale production.

The invention relates to a method for preparing a biologically active titanium dioxide film on a NiTi alloy surface, relating to a method for modification of a medical NiTi alloy surface and solving the technical problems of harsh conditions for micro-arc oxidation of the NiTi alloy with concentrated phosphoric acid as electrolyte in the prior art. In the method for preparing the biologically active titanium dioxide film on the NiTi alloy surface, concentrated sulfuric acid with the mass concentration being 98 percent is used as electrolyte, NiTi alloy is used as an anode, and a stainless steel tank is used as a cathode for micro-arc oxidation to obtained the biologically active titanium dioxide film on the NiTi alloy surface, or alkali treatment is carried out after micro-arc oxidation. By adopting the method, the titanium oxide film with a nanoscale porous structure and good biocompatibility can be prepared on the NiTi alloy surface, and the film and a substrate have high bonding strength of more than 45MPa. Moreover, the method is simple and can be used in clinical areas such as orthopedic surgery, department of stomatology, cardiovascular department, gynecology and the like.

The invention discloses an injectable self-solidifying calcium phosphate bone-repairing material and making method, which consists of solid phase and liquid phase, wherein the solid phase contains 0.2-2.0% degeneration starch, 0-15% beta-dicalcium silicate powder, 0-15% strontium and bismuth compound and 0-30% macromolecular microball or microcapsule; the liquid phase is composed of one or more composition of deionized water, diluted phosphoric acid, physiological saline, blood, soluble phosphate solution and organic acid; the rate of liquid phase and solid phase is 0.3-1.2ml / g.

The invention relates to a preparation method of brushite bone cement. The preparation method comprises the following steps: preparing an acidic bone cement solidification liquid by adopting a citric acid solution as a main body and adopting phosphorylated chitosan, hydroxypropyl methyl cellulose and gelatin as modifying agents; fully mixing monohydrate calcium dihydrogen phosphate, beta-tricalcium phosphate and SiO2 to obtain SiO2 modified brushite bone cement solid-phase powder; and mixing the bone cement solid-phase powder with the solidification liquid according to a solid-to-liquid ratio to obtain the brushite bone cement, wherein a solidification product comprises brushite as a main component. By adopting the preparation method disclosed by the invention, the solidification time of the brushite bone cement which adopts a conventional citric acid solution as the solidification liquid can be prolonged to be 6-20 minutes, and the flowability of blended slurry can be increased; and meanwhile, by virtue of complexing action of phosphorylated chitosan, solid-liquid separation of the blended slurry at a certain pressure can be avoided, and the comprehensive performance of the blended slurry can preferably meet the requirements of clinical application.

The invention relates to a spiral CT accurate reconstruction system based on a CELL wide-frequency engine, which belongs to the technical field of image processing, wherein, the data collected by a projection collecting module is stored in a memorizer of a data collector after the pretreatment of filtering and eliminating noise, and waits for the alternation with a DMA control module; the DMA control module selects the projection data required by the reconstruction from the projection collecting module and transmits the data into an image construction module; the image construction module adopts a spiral CT accurate reconstruction algorithm, firstly, a construction result in a PI coordinate system is obtained by a filter back-projection or back-projection filter construction algorithm, and then, a result in a Cartesian coordinate system is converted by the coordinate conversion by resetting the construction result in the PI coordinate system, finally, the construction result is stored and the construction image is given by a display output module. The spiral CT accurate reconstruction system of the invention optimizes the realization of the accurate construction algorithm according to an instruction set of a Cell chip, so as to enhance the parallel efficiency and the speedup ratio and improve the performance of the construction system.

A low-temp storage method for the tissue-engineered skin includes such steps as sample treating, treating in DMSO solution at 4 deg.C for 15 min, putting it in low-temp storage bag, sealing, and lowering temp at 1 deg.C / min of speed. Its advantage is high survival rate of cells (72.8-78%).

The invention provides a nucleophilic fluorination based synthetic method of F-BPA, a synthetic method of intermediates, the intermediates and an application of the intermediates. The nucleophilic fluorination based synthetic method of F-BPA comprises the following steps: 1, synthesizing a compound 2 from raw materials including a compound 1, dimethylamine hydrochloride and the like; 2, synthesizing a compound 3 from raw materials including the compound 2, methyl-trifluoromethanesulfonate and the like; 3, synthesizing a compound 4 from raw materials including the compound 3, K2.2.2 and the like; 4, synthesizing a compound 5 from raw materials including the compound 4, an NaBH4 aqueous solution, an HI aqueous solution and the like; 5, synthesizing the target product from raw materials including the compound 5, N-(diphenylmethyl)tert-butyl glycinate and the like under the catalytic action of an Maruoka chiral phase transfer catalyst.

The invention discloses a sustained-release suspension preparation containing levodopa and benserazide hydrochloride and a preparation method thereof. The sustained-release suspension preparation is prepared from cation exchange resin, levodopa, benserazide hydrochloride, an impregnating agent, plasticizers, suspending aids, framework materials, retardants and other auxiliary materials. The levodopa and the benserazide hydrochloride are firstly and respectively weighed; the weighed levodopa and the weighed benserazide hydrochloride are respectively mixed with the cation exchange resin; two kinds of medicine carrying resin are prepared; then, the two kinds of medicine carrying resin are respectively impregnated in the impregnating agent; after the impregnating is completed, the framework materials and the plasticizers are respectively used for preparing a medicine carrying resin microcapsule; finally, the suspending aids, the retardants and other auxiliary materials are added and are then mixed; the sustained-release suspension preparation is prepared. Compared with the prior art, the scheme has the advantages that the problem that old people are difficult to swallow solid medicineis solved; the adaptability of patients is obviously improved.

The invention relates to a sulfonated silk fibroin film modified polytetrafluoroethylene artificial blood vessel and a method for preparing the same.The method includes steps of carrying out low-temperature plasma surface pre-treatment on a polytetrafluoroethylene artificial blood vessel, vertically or obliquely arranging the polytetrafluoroethylene artificial blood vessel, sealing one end of the polytetrafluoroethylene artificial blood vessel, forming an opening in the other end of the polytetrafluoroethylene artificial blood vessel, keeping the opening upwards, injecting 0.5-2.0 mg / mL silk fibroin solution into the polytetrafluoroethylene artificial blood vessel from the opening, evaporating the silk fibroin solution and coating the silk fibroin solution in the polytetrafluoroethylene artificial blood vessel; turning the polytetrafluoroethylene artificial blood vessel over, keeping the opening upwards, injecting 0.5-2.0 mg / mL silk fibroin solution into the polytetrafluoroethylene artificial blood vessel from the opening, evaporating the silk fibroin solution and coating the silk fibroin solution in the polytetrafluoroethylene artificial blood vessel to obtain a silk fibroin film modified polytetrafluoroethylene artificial blood vessel, and carrying out low-temperature plasma surface sulfonation treatment on the silk fibroin film modified polytetrafluoroethylene artificial blood vessel to obtain the sulfonated silk fibroin film modified polytetrafluoroethylene artificial blood vessel.The sulfonated silk fibroin film modified polytetrafluoroethylene artificial blood vessel and the method have the advantages that the sulfonated silk fibroin film modified polytetrafluoroethylene artificial blood vessel prepared by the aid of the method is good in uniformity and excellent in blood and tissue compatibility and rarely has chap and crack.

A method for treating human placenta cells samples and the human placental cells samples obtained by the method, a method for constructing human placental mesenchymal cells' library and the human placental mesenchymal cells' library obtained by the method, the uses of the obtained human placenta cells samples and the human placental mesenchymal cells' library in treating human dysfunction or diseases caused by cells injury or cells dysfunction, and the method for treating human dysfunction or diseases caused by cells injury or cells dysfunction are provided. A method for searching human placental cells in the library and a method for preparing human umbilical cord blood serum are also provided.

The invention provides a nucleophilic fluorination based synthetic method of F-BPA, a synthetic method of intermediates, the intermediates and an application of the intermediates. The nucleophilic fluorination based synthetic method of F-BPA comprises the following steps: 1, synthesizing a compound 2 from raw materials including a compound 1, dimethylamine hydrochloride and the like; 2, synthesizing a compound 3 from raw materials including the compound 2, methyl-trifluoromethanesulfonate and the like; 3, synthesizing a compound 4 from raw materials including the compound 3, K2.2.2 and the like; 4, synthesizing a compound 5 from raw materials including the compound 4, an NaBH4 aqueous solution, an HI aqueous solution and the like; 5, synthesizing the target product from raw materials including the compound 5, N-(diphenylmethyl)tert-butyl glycinate and the like under the catalytic action of an Maruoka chiral phase transfer catalyst.

The invention provides an intermediate compound, and a synthetic method and an application for the intermediate compound. The method comprises the following steps: adding a compound 1 and dimethylammonium hydrochloride into a solvent mixed by dimethylsulfoxide and water, adding K2CO3 for two times or more, and carrying out a reflux reaction under heating for 6 h to 36 h, wherein the mol ratio of the compound 1 to the dimethylammonium hydrochloride to the K2CO3 is 1: (1-5): (1-5); and after completion of the reaction, carrying out separation and purification so as to obtain the intermediate compound. The intermediate compound provided by the invention is mainly applied to F-BPA nucleophilic fluorination synthesis.

The invention provides an intermediate compound, and a synthetic method and an application for the intermediate compound. The method comprises the following steps: dissolving a compound 4 in water, then adding an obtained mixture into a tC18 column, flushing the column with water, and carrying out blowing with gas so as to discharge an excess liquid; adding an NaBH4 aqueous solution, carrying outa reaction for 2 minutes or above, flushing the column with water, and carrying out blowing with gas so as to discharge an excess liquid; and adding an HI aqueous solution, carrying out a reaction for2 minutes or above, discharging an excess liquid by using gas, and carrying out elution with toluene so as to obtain an intermediate compound dissolved toluene solution, wherein the mole ratio of thecompound 4 to NaBH4 to HI is 1: (1-5): (1-5). The intermediate compound provided by the invention is mainly applied to F-BPA nucleophilic fluorination synthesis.

The invention provides a method for preparing drug-loaded injection type calcium sulfate bone cement for promoting bone growth. The method comprises the following steps: mixing calcium sulfate hemihydrate, drug-loaded beta-tricalcium phosphate and hydroxyapatite to obtain modified calcium carbonate bone cement solid phase powder, and preparing a neutral bone cement curing liquid by using sodium phosphate as a main body and phosphorylated chitosan, hydroxypropyl methyl cellulose and gelatin as modifying agents to improve the injectable property of the formula; and mixing the bone cement solid phase powder with the curing liquid, and adding main ingredients of a curing product, namely brushite and hydroxyapatite which have better degrading capability in an organism. The drug-loaded injection type calcium sulfate bone cement is simple in raw materials and easy in preparation process, and can be used for large-scale production. The formula of the bone cement has a remarkable effect for improving the curing time and injection property of the calcium sulfate bone cement, has a drug-loading function, and has a wide application prospect in the field of clinical tissue repairing.

This invention discloses a cell cultivatioin device including: a cell cultivation tank with an inlet for seed cells, an inlet for nutrient fluid and a stromal cell adding port on one end, the other end is set with an outlet for cultivated cells, an outlet for metabolized waste solution and a discharge port for stromal cells, at least two supplying tubes for nutrient fluid, one metabolized waste solution reclaim tube and two cell cultivation tubes are set in the cell cultivation tank, other places of which are fully filled with stromal cells, a nutrient fluid circulation device connected with the inlet of the nutrient fluid and the wasted outlet of the cell cultivation tank, a cell providing device connected with the seed cell inlet of the tank and a cell collecting device connected with the outlet of the cultivated cells of the tank.

The invention provides a method for detecting MFG-E8. The method includes 1), preparing detection samples and standard substances; 2), coating and adsorbing anti-human MFG-E8 protein mouse monoclonalantibodies in coated plates; 3), allowing the detection samples and the standard substances to be in contact with the coated anti-human MFG-E8 protein mouse monoclonal antibodies, adding anti-human MFG-E8 protein sheep polyclonal antibodies, anti-sheep IgG rabbit antibodies labeled by horseradish peroxidase and luminescence substrates into the detection samples and the standard samples, allowing the detection samples and the standard substances to be in contact with the anti-human MFG-E8 protein sheep polyclonal antibodies, the anti-sheep IgG rabbit antibodies labeled by the horseradish peroxidase and the luminescence substrates, carrying out light protective reaction, measuring chemiluminescence values and computing the content of the MFG-E8 in the detection samples. The method has the advantages that the method is good in precision, low in detection limit, high in sensitivity and wide in linear range, clinical application requirements can be met, and the like.

The invention discloses a deep cryoprotectant for skin, which mainly consists of dimethyl sulfoxide, cell culture medium, human serum albumin, maltodextrin and urea, wherein dimethyl sulfoxide, cell culture medium, human blood Albumin constitutes the base fluid, in which dimethyl sulfoxide accounts for 5% to 12%, human serum albumin accounts for 5% to 10%, and the balance is cell culture medium, calculated by volume percentage; maltodextrin The concentration is 10%-20%, and the concentration of urea is 0.5%-1.5%. The skin cryoprotectant of the invention can be used for cryoprotection of human allogeneic skin. The cell survival rate of human allogeneic skin preserved by the preservation method of the present invention is high, and the biological properties of the skin graft have little change, which is conducive to the rapid generation of granulation tissue at the transplantation site of the patient, improves the success rate of replantation, and shortens the treatment time of the patient at the same time. time and reduce treatment costs.

The invention belongs to the technical field of stem cell culture. More specifically, it relates to a culture method and serum-free medium for promoting the proliferation and differentiation of mesenchymal stem cells. It includes the following components: 0.1-3.5% of human platelet lysate, 1-3 mmol / L of L-glutamine, 5-30 μg / mL of vitamin C derivatives, and the basal medium is supplemented to 1 L. The serum-free medium of the present invention adds lentinan and 2-O-ether ascorbic acid, realizes that only a relatively low concentration of platelet lysate can meet the needs of continuous expansion and culture of mesenchymal stem cells in vitro, and can be well The ability to maintain the proliferation and high differentiation of mesenchymal stem cells greatly reduces the cost of culture and the risk of clinical application.

The invention provides an automatic ventricular septum jitter detection system based on an ultrasonic image, and relates to the technical field of computer vision. The system firstly obtains a plurality of echocardiograms with SF labels as a sample data set; then initializing a deep neural network model for ventricular septum jitter detection, and pre-training the deep neural network model by using the sample data set to obtain a pre-trained deep neural network model, wherein the deep neural network model used for ventricular septum jitter detection comprises a left ventricular segmentation network U-Net and a codec-based SF diagnosis network; and finally, loading model parameters and a configuration file of the pre-trained deep neural network model, segmenting the left ventricle in the echocardiogram to be evaluated, and outputting a ventricular septum jitter judgment result. According to the detection system, a deep learning method is used for automatically segmenting the left ventricle, automatic diagnosis of the SF is achieved according to the segmentation result, the clinical diagnosis time is shortened, and result differences caused by subjective experience of doctors are avoided.

The invention relates to a preparation method of bone cement catalytically cured by acidic HA (hydroxyapatite). According to the method, calcium phosphate monobasic monohydrate, beta-tricalcium phosphate and citric acid-modified HA are mixed, and modified brushite bone cement solid-phase powder is obtained, wherein the modified HA plays a catalytic curing role; sodium phosphate serves as a main body, phosphorylated chitosan, hydroxypropyl methyl cellulose and gelatin serve as a modifying agent, a neutral bone cement curing liquid is prepared, and an original acidic formula is improved; the bone cement solid-phase powder and the curing agent are mixed in a certain solid-to-liquid ratio, and a curing product comprises main components including brushite and HA and has the higher degradation ability in organisms. Used raw materials are simple, the preparation process is simple, and large-scale production can be realized. The bone cement formula has the significant improvement effect on curing time and syringeability of brushite bone cement and has broad application prospect in the field of clinical bone tissue repair.

The invention discloses an injectable self-curing calcium phosphate bone repair material and a preparation method thereof. The material is composed of a solid phase and a liquid phase. The solid phase is calculated by 100 parts by mass of polybasic calcium phosphate salt, and 0.2-2.0 parts by mass of modified starch. 0-15 parts by mass of β-dicalcium silicate powder, 0-15 parts by mass of strontium and bismuth compounds, 0-30 parts by mass of polymer microspheres or microcapsules; deionized water, dilute phosphoric acid, and normal saline are used as the liquid phase , blood, soluble phosphate solution, organic acid or a mixture of more than one; according to the ratio of liquid phase to solid phase: 0.3 ~ 1.2ml / g evenly reconciled. This material has good comprehensive performance and can meet the requirements of clinical application, and is suitable for bone defect repair, osteoporosis treatment and fracture fixation and treatment in orthopedics, spine surgery, plastic surgery and stomatology.

The invention provides an intermediate compound, and a synthetic method and an application for the intermediate compound. The method comprises the following steps: adding a compound 1 and dimethylammonium hydrochloride into a solvent mixed by dimethylsulfoxide and water, adding K2CO3 for two times or more, and carrying out a reflux reaction under heating for 6 h to 36 h, wherein the mol ratio of the compound 1 to the dimethylammonium hydrochloride to the K2CO3 is 1: (1-5): (1-5); and after completion of the reaction, carrying out separation and purification so as to obtain the intermediate compound. The intermediate compound provided by the invention is mainly applied to F-BPA nucleophilic fluorination synthesis.

The invention discloses a calcium phosphate bone cement subjected to temperature regulation degradation, wherein the preparation raw materials comprise calcium phosphate bone cement liquid phase agentand solid phase powder which are matched when used; the liquid phase agent is a common calcium phosphate bone cement liquid phase agent; the solid phase powder is a mixture of a temperature-sensitiveoxygen generating compound and common calcium phosphate cement solid phase powder; the temperature-sensitive oxygen generating compound is a sodium percarbonate-wax microsphere compound coated with alayer of gelatin on the surface, the sodium percarbonate-wax microsphere compound is a sodium percarbonate microsphere compound coated with a layer of wax on the surface. The invention also disclosesa preparation method of the calcium phosphate bone cement subjected to temperature regulation degradation, the degradation rate of the calcium phosphate bone cement can be accelerated through heat treatment, and the calcium phosphate bone cement has good safety performance and is suitable for mass production.

The invention discloses a calcium phosphate bone cement degradable under regulation. The calcium phosphate bone cement is prepared from the following raw materials: a liquid-phase agent and a solid-phase powder. The liquid-phase agent is a common calcium phosphate bone cement liquid-phase agent or a mixed liquid of a two-dimensional black phosphorus nano-material dispersion liquid and the common calcium phosphate bone cement liquid-phase agent, wherein the two-dimensional black phosphorus nano-material dispersion liquid is a mixed liquid of a two-dimensional black phosphorus nano-material anddeionized water. The solid-phase powder is a mixture of a temperature-sensitive oxygen-produced compound and a calcium phosphate bone cement solid-phase powder, wherein the temperature-sensitive oxygen-produced compound is a sodium percarbonate-wax microsphere composite suface-coated with a gelatin layer, and the sodium percarbonate-wax microsphere composite is a sodium percarbonate microsphere composite coated with a wax layer. The invention also discloses a preparation method for the above-mentioned calcium phosphate bone cement degradable under regulation. The calcium phosphate bone cementprepared in the invention can be accelerated in degradation rate through both heat treatment and near-infrared light treatment, and is good in safety and suitable for mass production.

The invention relates to a method for preparing high-strength novel hydroxyapatite bone cement. The method comprises the following step of blending single-phase hydroxyapatite powder, which is subjected to surface modification by virtue of a phytic acid solution, as solid powder and a low-concentration citric acid aqueous solution as a curing liquid at a certain solid-liquid ratio to obtain the high-strength novel hydroxyapatite bone cement. The bone cement has higher compressive strength which can reach up to 66MPa and is much higher than that of the bone cement using existing single-phase hydroxyapatite as the solid powder, good biocompatibility and operability, the curing process does not rely on an acid-base reaction and the heat release rate is very low, the bone cement is neutral and the excellent performance meets the requirements of clinical applications and the hydroxyapatite bone cement can be applicable to the repair of hard tissue bone defects, treatment of osteoporosis and fixation and treatment of bone fracture.

The invention provides an intermediate compound, an intermediate compound synthetic method and an application thereof. The method comprises the following steps: under inert gas protection, a dichloromethane solution of a compound 2 and a dichloromethane solution of methyl-trifluoromethyl sulfonate are mixed, a mixture is subjected to stirring reaction for 3-12 h, wherein the mol ratio of the compound 2 to methyl-trifluoromethyl sulfonate is 1:1-5; and after the reaction, the material is subjected to separating purification to obtain the intermediate compound. The intermediate compound is mainly used for F-BPA Nucleophilic fluorination synthesis.

The invention relates to a preparation method of desloratadine. The preparation method comprises the following steps: (1) dissolving loratadine into an alcohol solvent with the volume concentration of 55-75% under the protection of nitrogen, adding potassium hydroxide, heating to 70-75 DEG C, beginning reflux reaction, controlling the temperature of the reflux reaction to keep a gradient change within 70-100 DEG C, and refluxing till complete reaction of the loratadine; (2) adding an ethyl acetate solvent into a completely reacted reaction solution for extracting, draining out a water layer, repeating the extracting step for 2-3 times, washing by using water, and crystallizing, decolorizing and recrystallizing to obtain desloratadine. By the preparation method, the technical problems that in the prior art, the product desloratadine cannot meet a requirement for purity, contains many impurities, and cannot meet requirements on clinical application are solved.

The invention provides an intermediate compound, an intermediate compound synthetic method and an application thereof. The method comprises the following steps: under inert gas protection, a dichloromethane solution of a compound 2 and a dichloromethane solution of methyl-trifluoromethyl sulfonate are mixed, a mixture is subjected to stirring reaction for 3-12 h, wherein the mol ratio of the compound 2 to methyl-trifluoromethyl sulfonate is 1:1-5; and after the reaction, the material is subjected to separating purification to obtain the intermediate compound. The intermediate compound is mainly used for F-BPA Nucleophilic fluorination synthesis.

The invention relates to a spiral CT accurate reconstruction system based on a CELL wide-frequency engine, which belongs to the technical field of image processing, wherein, the data collected by a projection collecting module is stored in a memorizer of a data collector after the pretreatment of filtering and eliminating noise, and waits for the alternation with a DMA control module; the DMA control module selects the projection data required by the reconstruction from the projection collecting module and transmits the data into an image construction module; the image construction module adopts a spiral CT accurate reconstruction algorithm, firstly, a construction result in a PI coordinate system is obtained by a filter back-projection or back-projection filter construction algorithm, andthen, a result in a Cartesian coordinate system is converted by the coordinate conversion by resetting the construction result in the PI coordinate system, finally, the construction result is storedand the construction image is given by a display output module. The spiral CT accurate reconstruction system of the invention optimizes the realization of the accurate construction algorithm accordingtoan instruction set of a Cell chip, so as to enhance the parallel efficiency and the speedup ratio and improve the performance of the construction system.